ArticleBMC cancer2025
Health inequality and the global burden of mesothelioma: insights from the global burden of disease study 2021.
Article in BMC cancer, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed.
- Burden of Mesothelioma in China, 1990-2023: Trends, Decomposition, and Projections Until 2045.Cancers · 2026Article
- Burden, Trends, and Future Projections of Multiple Myeloma in China from 1990 to 2023.Cancers · 2026Article
- New anti-mesothelioma compounds, paramyfurans and paramylactone, produced by Paramyrothecium sp. BF-1049.The Journal of antibiotics · 2026Article
- Global, regional and national burden of colorectal cancer attributable to low-fiber diet from 1990 to 2021: a systematic analysis of the global burden of disease study 2021.Frontiers in nutrition · 2026Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThis study aims to systematically analyze the disease burden and epidemiological trends of mesothelioma at the global, regional, and national levels from 1990 to 2021, based on the Global Burden of Disease (GBD) 2021 database, and to explore its relationship with health inequality.
methodDALYs were calculated by integrating Years of Life Lost due to premature mortality (YLL) and Years Lost due to disability (YLD) to comprehensively assess the disease burden. Additionally, the study analyzes cross-country health inequalities using the Slope Index of Inequality (SII) and the Concentration Index (CI).
resultsOver the past 32 years, global mesothelioma prevalence, incidence, DALYs, and death cases have increased significantly. In 2021, prevalence and incidence rates were highest in the high SDI regions, while the fastest growth occurred in the middle SDI regions. At the national level, Qatar, Bahrain, and Kuwait experienced the largest increases. The 75–79 age group had the highest prevalence and death cases globally. The analysis of health inequity indicates that countries with higher SDI levels are facing a more severe disease burden.
conclusionFrom 1990 to 2021, the disease burden of mesothelioma exhibited a sustained upward trend. The widening gap in DALYs rates between countries with the highest and lowest SDI levels highlights the growing health inequality. Therefore, there is an urgent need for effective public health policies aimed at reducing occupational exposure, alleviating disease burden, and narrowing health disparities between countries.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.